RecruitingNot ApplicableNCT06451536

Ga-68 FAPI PET Before Immunotherapy

Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma

Sponsor

Ankara University

Enrollment

30 participants

Start Date

Apr 30, 2024

Study Type

INTERVENTIONAL

Conditions

Mesotheliomas Pleural

Summary

It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Having a histopathologically confirmed diagnosis of
Pleural Mesolthelioma
Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
Patients who gave informed consent form to participate in the study

Exclusion Criteria2

ECOG\>2
Patients who did not provide informed consent form to participate in the study

Interventions

DIAGNOSTIC_TESTGa-68 FAPI PET/CT

imaging of FAP expression of tumor before immunotherapy

Locations(1)

Ankara University School of Medicine

Ankara, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06451536

Related Trials

Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

NCT071265091 location

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

NCT037605751 location